NCT06072625

Brief Summary

It is a two-arm prospective interventional study. 40 babies in both groups will be enrolment in the study. In the intervention group, babies will take 1 ml/kg/day of the study product (ULTRA PREMIUM) after full enteral feeding. Supplementation will continue until discharge or the 36th week. Blood samples will be taken for serum Total antioxidant capacity and Malondialdehyde levels before the intervention and on the 14th day of the control group. At the end of the study, serum will be taken again for control values. Daily lipid intake amounts will be recorded through breast milk analysis. Lipid profile will be monitored weekly The growth parameters of babies will be monitored daily It will be evaluated at the end of the study in terms of ROP, BPD, and NEC. At the end of the study, the data of babies in both groups will be compared.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 13, 2023

Completed
18 days until next milestone

Study Start

First participant enrolled

October 1, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 10, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2025

Completed
Last Updated

July 15, 2024

Status Verified

July 1, 2024

Enrollment Period

1.3 years

First QC Date

September 13, 2023

Last Update Submit

July 12, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of patients who completed the study

    To enrolment of 40 babies in the study in both groups

    15 months

  • Postnatal growth retardation rates

    Daily weight intake amounts of babies in both groups

    18 months

Secondary Outcomes (1)

  • Frequency and severity of retinopathy of prematurity

    18 months

Study Arms (2)

Olive oil group

ACTIVE COMPARATOR

Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil

Dietary Supplement: Extra virgin organic olive oil (ULTRA PREMIUM)

Control group

NO INTERVENTION

Interventions

Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil

Olive oil group

Eligibility Criteria

Age14 Days - 40 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Premature babies born at 32 weeks or less
  • Babies who tolerate full enteral feeding at the before end of the second week
  • Babies given consent by their parents -

You may not qualify if:

  • Having a congenital or genetic anomaly

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bursa City Hospital

Bursa, 16110, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Central Study Contacts

Ayten Erdoğan Ordu, MD

CONTACT

Murat Tutanc, Prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Division of Neonatology, Associate Professor

Study Record Dates

First Submitted

September 13, 2023

First Posted

October 10, 2023

Study Start

October 1, 2023

Primary Completion

December 31, 2024

Study Completion

March 31, 2025

Last Updated

July 15, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Locations